Cumberland Pharmaceuticals (CPIX) Amortization of Deferred Charges (2010 - 2026)
Cumberland Pharmaceuticals (CPIX) posted Amortization of Deferred Charges of $285184.0 for Q1 2026, up 134.26% sequentially from -$832368.0 in Q4 2025, and up 5218.61% YoY from $5362.0 in Q1 2025.
Cumberland Pharmaceuticals (CPIX) Amortization of Deferred Charges (2010 - 2026) Analysis & Trends
Cumberland Pharmaceuticals has reported Amortization of Deferred Charges for 17 years, with the latest figure at $285184.0 in Q1 2026.
- Quarterly Amortization of Deferred Charges rose 5218.61% year-over-year to $285184.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $303007.0 (down 73.47% YoY) and the FY2025 annual result came in at $23185.0, down 97.97% from the prior year.
- Amortization of Deferred Charges grew to $285184.0 in Q1 2026 per CPIX's latest filing, from -$832368.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $846899.0 in Q3 2024 and troughed at -$832368.0 in Q4 2025.
- A 5-year average of $134990.8 and a median of $4844.0 in 2024 frame the typical range for Amortization of Deferred Charges.
- The widest YoY moves for Amortization of Deferred Charges: up 22572.55% in 2023, down 6403.68% in 2023.
- Over 5 years, Amortization of Deferred Charges stood at $3629.0 in 2022, then soared by 22572.55% to $822787.0 in 2023, then plunged by 65.34% to $285185.0 in 2024, then slumped by 391.87% to -$832368.0 in 2025, then jumped by 134.26% to $285184.0 in 2026.
- According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $285184.0, -$832368.0, and $285184.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Cumberland Pharmaceuticals | 114.46 Mn | 110.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 196,139.00 |
| Jun 30, 2026 | 196,139.00 |
| Mar 31, 2026 | 285,184.00 |
| Mar 31, 2026 | 285,184.00 |
| Dec 31, 2025 | -832,368.00 |
| Dec 31, 2025 | -832,368.00 |
| Sep 30, 2025 | 285,184.00 |
| Sep 30, 2025 | 285,184.00 |
| Jun 30, 2025 | 565,007.00 |
| Jun 30, 2025 | 565,007.00 |
| Mar 31, 2025 | 5,362.00 |
| Mar 31, 2025 | 5,362.00 |
| Dec 31, 2024 | 285,185.00 |
| Dec 31, 2024 | 285,185.00 |
| Sep 30, 2024 | 846,899.00 |
| Sep 30, 2024 | 846,899.00 |
| Jun 30, 2024 | 4,844.00 |
| Jun 30, 2024 | 4,844.00 |
| Mar 31, 2024 | 3,810.00 |
| Mar 31, 2024 | 3,810.00 |